Pyxis Oncology, Inc. Form 8-K Summary
Business Context and Reporting Period
Pyxis Oncology, Inc., a Delaware biopharmaceutical company listed on Nasdaq under the symbol PYXS, filed this Form 8-K on August 9, 2022, reporting an event that occurred on August 3, 2022.
Financial and Operating Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial metrics.
Material Change Versus Prior Period
Effective August 3, 2022, Jitendra Wadhane was appointed Chief Accounting Officer and Principal Accounting Officer. He had served as the company’s Senior Vice President of Finance and Corporate Controller since August 2021.
Management Commentary, Risks, and Unusual Items
- Mr. Wadhane previously served as Head of SEC Reporting and Technical Accounting at Immunovant, Inc. and as a Senior Manager at Ernst & Young LLP.
- He is a Certified Public Accountant and holds a bachelor’s degree from the University of Mumbai and a Chartered Accountancy qualification from the Institute of Chartered Accountants of India.
- The filing states that Mr. Wadhane has no family relationships with any director or executive officer and no reportable related-party transactions under Item 404(a) of Regulation S-K.
- The filing discloses no arrangements or understandings with other persons regarding his selection.
Investor Verification Items
- Verify the effective date and scope of Mr. Wadhane’s Chief Accounting Officer and Principal Accounting Officer roles.
- Review subsequent filings for any changes in the company’s finance and accounting leadership.
- Consult the company’s financial filings separately for operating results, cash runway, liquidity, and financing risks, which are not addressed in this Form 8-K.